Prostatype Genomics AB (OSTO:PROGEN) Operating Margin %: -5,422.99% (As of Dec. 2025)


OSTO:PROGEN Prostatype Genomics AB OSTO:PROGEN
25 GF Score
Price kr0.43
GF Value kr0.11
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Prostatype Genomics AB Operating Margin %?

Prostatype Genomics AB OSTO:PROGEN -4.23% 25 Operating Margin % is -5,422.99% as of Dec. 2025. GuruFocus rates OSTO:PROGEN with a GF Score™ of 25/100 and a GF Value™ of kr0.11 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Prostatype Genomics AB ranks worse than 97.04% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Prostatype Genomics AB's Operating Income for the six months ended in Dec. 2025 was kr-18.87 Mil. Prostatype Genomics AB's Revenue for the six months ended in Dec. 2025 was kr0.35 Mil. Therefore, Prostatype Genomics AB's Operating Margin % for the quarter that ended in Dec. 2025 was -5,422.99%.

Good Sign:

Prostatype Genomics AB operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Prostatype Genomics AB's Operating Margin % or its related term are showing as below:

OSTO:PROGEN' s Operating Margin % Range Over the Past 10 Years
Min: -155480   Med: -6555.22   Max: -2894.32
Current: -6555.05


OSTO:PROGEN's Operating Margin % is ranked worse than
97.04% of 203 companies
in the Medical Diagnostics & Research industry
Industry Median: -3.29 vs OSTO:PROGEN: -6555.05

Prostatype Genomics AB's 5-Year Average Operating Margin % Growth Rate was 22.40% per year.

Prostatype Genomics AB's Operating Income for the six months ended in Dec. 2025 was kr-18.87 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was kr-38.94 Mil.

Warning Sign:

Prostatype Genomics AB has never been profitable in the past 3 years. It lost money every year.


Prostatype Genomics AB  (OSTO:PROGEN) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Prostatype Genomics AB Operating Margin % Related Terms


Prostatype Genomics AB Operating Margin % Historical Data

* Premium members only.

The historical data trend for Prostatype Genomics AB's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prostatype Genomics AB Operating Margin % Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial -155,480.00 -4,200.44 -2,894.32 -20,529.65 -6,555.22

Prostatype Genomics AB Semi-Annual Data
Jun18 Jun19 Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,063.22 -16,870.43 -25,538.10 -8,156.50 -5,422.99

OSTO:PROGEN vs TMO, DHR, IDXX: Operating Margin % Comparison

For the Diagnostics & Research subindustry, Prostatype Genomics AB's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prostatype Genomics AB Operating Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Prostatype Genomics AB's Operating Margin % falls into.


OSTO:PROGEN
25GF Score
Prostatype Genomics AB OSTO:PROGEN
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prostatype Genomics AB Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Prostatype Genomics AB's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-38.938 / 0.594
=-6,555.22 %

Prostatype Genomics AB's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-18.872 / 0.348
=-5,422.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -5,422.99% mean?
Prostatype Genomics AB (OSTO:PROGEN) has a Operating Margin % of -5,422.99% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Prostatype Genomics AB and its competitors. According to the industry distribution chart, Prostatype Genomics AB ranks #197 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 97%.
Is Prostatype Genomics AB's Operating Margin % too high?
Prostatype Genomics AB's current Operating Margin % is -5,422.99%. Based on the distribution chart, Prostatype Genomics AB ranks #197 out of 203 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Prostatype Genomics AB has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's Operating Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Prostatype Genomics AB ranks #197 out of 203 companies for Operating Margin %. This places Prostatype Genomics AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Diagnostics & Research company?
A good Operating Margin % depends on the Medical Diagnostics & Research industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Prostatype Genomics AB and its competitors. Prostatype Genomics AB's current Operating Margin % is -5,422.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.11, compared to a current price of kr0.43 — trading 290.9% above its estimated fair value. The current Operating Margin % is -5,422.99%. Prostatype Genomics AB's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current Operating Margin % is -5,422.99% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued. The current stock price of kr0.43 is trading 290.9% above its estimated GF Value™ of kr0.11. GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.

Key valuation signals for OSTO:PROGEN:

  • Operating Margin %: -5,422.99%
  • GF Value™: kr0.11 vs. price of kr0.43 (290.9% above fair value)
  • GF Score™: 25/100 with 5 warning signs

No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Prostatype Genomics AB Business Description

Address Augustendalsvagen 20, Nacka Strand, SWE, 131 52
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
25GF Score

Get the complete analysis for OSTO:PROGEN

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.43
Price
kr0.11
GF Value